The global PET Scanners Market is projected to grow from an estimated USD 2.0 billion in 2022 to over USD 3.02 billion by 2030, according to a new industry report. This equates to an impressive 5.3% compound annual growth rate (CAGR) over the 2023-2030 forecast period. Driving this sustained market expansion is the increasing clinical utility of PET molecular imaging across crucial areas like oncology, neurology and cardiology coupled with technological advancements in hybridized PET/CT and PET/MRI systems.
PET is a powerful functional and molecular imaging technique that maps the distribution of radioactive tracers, or biomarkers, injected into the body. By collecting emissions from these radiotracers concentrated in tissues of interest, PET scanners can reveal metabolic processes at the cellular level—information invisible to conventional anatomical imaging modalities like CT or MRI alone. The most common PET applications today revolve around detecting and monitoring cancer, evaluating neurological conditions like Alzheimer’s disease, and assessing cardiovascular pathologies.
“PET molecular imaging opens a window into the biochemistry underlying diseases in vivo, rather than just showing structural abnormalities,” said Dr. Johannes Czernin, Chief of the Ahmanson Biological Imaging Division at the University of California, Los Angeles (UCLA). “Thanks to its unmatched sensitivity, specificity and quantification capabilities, PET is increasingly vital for precisely diagnosing and staging disease, monitoring therapeutic efficacy, and accelerating development of new targeted drugs across many areas of medicine.”
Download Free Sample Report of PET Scanners Market @ https://www.snsinsider.com/sample-request/4152
Rise in Cancer Burden Drives Clinical Adoption
The global burdens imposed by cancer represent a major force propelling increased adoption of PET scanning technology across healthcare systems worldwide. According to GLOBOCAN statistics published in 2022, there were over 19 million new cancer cases diagnosed and 10 million cancer deaths globally. Earlier and more accurate detection at potentially curable stages is an urgent priority to improve outcomes.
PET with 18F-FDG radiotracer is the molecular imaging gold standard for cancer diagnosis, staging and treatment monitoring. Research shows PET/CT is more accurate than conventional CT and MRI for detecting, characterizing and quantifying tumor malignancies based on their metabolic signatures. PET also enables assessment of treatment response much earlier based on metabolic changes rather than relying on delaylggyed anatomical indicators.
Because of these clinical benefits for cancer patient management, healthcare providers and insurers recognize the value of PET/CT and other PET-based techniques, steadily expanding global installed based especially in hospitals and oncology imaging centers.
Hybridized PET/CT and Innovations Drive Growth
Within the overall PET scanners market landscape, combined PET/CT and PET/MRI systems represent the predominant revenue share at around 70% globally. These integrated hybrid systems that overlay functional metabolic PET data onto CT or MRI anatomical imaging have improved diagnostic accuracy while streamlining clinical workflows.
“The game-changer was the introduction of PET/CT systems around the early 2000s, which took adoption to new heights. Today PET/MRI represents the next transformative multimodality frontier,” remarked Dr. Czernin. “By complementing excellent soft tissue anatomic detail from MRI with PET’s metabolic and molecular imaging data, new clinical applications in oncology, neurology and cardiovascular disease are rapidly emerging.”
Beyond hybridization, other promising technological innovations continue to propel the PET scanners market forward. For example, digital silicon photomultiplier PET detectors offer higher sensitivity and faster data acquisition speeds compared to conventional analog PET detectors. Digital PET/CT scanners like Siemens’ Biograph Vision are disrupting the market with up to 2x improvement in quantitative lesion detection and overall imaging quality.
Similarly, longer axial field-of-view systems that can perform total-body scans with a single rotation are advancing into clinical reality. The potential to radically reduce PET scan times from 20+ minutes to just 1-2 minutes with very low radiation doses while maximizing quantitative accuracy could improve patient experiences while opening new avenues for dynamic functional imaging in drug development.
Additionally, developers continue expanding the arsenal of novel radiotracers that can probe and characterize specific disease pathways like protein misfolding, inflammation, cell proliferation and death pathways. Validating the clinical utilities of these smarter, targeted PET radiotracers stands to create new applications and revenue streams across the entire molecular imaging market.
Regional Market Dynamics
Currently, North America captures around 45% of the global PET scanning market, led by the United States. This dominant position is attributable to the well-established clinical adoption and reimbursement coverage for oncology and other PET applications, as well as major investments in molecular imaging technologies by the region’s premier academic institutions and life sciences industry.
Europe represents the second-largest regional PET scanners market, accounting for roughly one-quarter of global revenues. However, the Asia Pacific region is projected to experience the most robust growth at over 6.5% CAGR through 2030 as developing economies like China, India and others rapidly establish molecular imaging infrastructure and clinical expertise to modernize oncology and neurology services.
As Dr. Czernin summarized: “Molecular imaging with PET stands at the vanguard of precision medicine by enabling us to visualize disease processes directly at their biological sources and then apply that exquisitely specific information to optimize therapies and develop smarter treatments, faster. The immense value PET technologies provide across the entire healthcare spectrum will keep this market growing steadily worldwide.”
Key Takeaways:
- PET scanners market projected to reach $3.02B by 2030, up from estimated $2.0B in 2022
- 5.3% CAGR driven by increased clinical adoption for oncology, neurology, cardiology applications
- Hybridized PET/CT and PET/MR systems driving around 70% of current sales globally
- Innovations like digital detectors, total-body PET, novel radiotracers accelerating capabilities
- North America and Europe lead but Asia-Pacific is fastest-growing regional market
- Potential for molecular imaging to advance precision medicine fueling long-term growth runway
The rising burden of debilitating diseases like cancer, unmet needs for earlier detection and treatment optimization, and the proven quantitative benefits molecular imaging can provide are catalyzing healthcare’s transition toward broader adoption of PET scanning technologies worldwide. With reimbursement coverage expanding and powerful technological innovations simplifying and enhancing PET’s clinical performance, this modality stands poised for sustained growth in the years ahead.
Other Trending Reports
Respiratory Syncytial Virus (RSV) Therapeutics Market Size
